PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy

Yu, MC; Chen, Z; Zhou, Q; Zhang, B; Huang, JL; Jin, L; Zhou, BH; Liu, S; Yan, JL; Li, XQ; Zhang, WT; Liu, CX; Hu, B; Fu, PY; Zhou, CH; Xu, YF; Xiao, YS; Zhou, J; Fan, J; Ren, N; Hung, MC; Guo, L; Li, H; Ye, QH

Ren, N; Guo, L; Li, H; Ye, QH (通讯作者)，Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Dept Liver Surg & Transplantat,Minist Educ,Key La, Shanghai 200032, Peoples R China.;Hung, MC (通讯作者)，China Med Univ, Res Ctr Canc Biol, Grad Inst Biomed Sci, Taichung 404, Taiwan.;Hung, MC (通讯作者)，China Med Univ, Ctr Mol Med, Taichung 404, Taiwan.

JOURNAL OF HEPATOLOGY, 2022; 77 (1): 140

Abstract

Background & Aims: Although the treatment of hepatocellular carcinoma (HCC) has been revolutionized by the advent of effective systemic therapies,......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索